



Bal Pharma Limited

To,
The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

29/07/2020

BSE Limited
Mumbai.

Dear Sir,

Sub : Outcome of the Board Meeting.

As informed to the exchanges, the meeting of Board of Directors of the Company was held to day and the Board has inter alia transacted the following business.

1.Approved the Audited stand alone and consolidated Financial Results of the Company for the quarter and Financial Year ended 31.03.2020. We are submitting a copy of the Audited stand alone and Consolidated financials results along with Balance Sheet , Cash Flow Statements and Auditors reports.

2.Approved the Audited standalone and consolidated accounts of the Company for F.Y ended 31.03.2020 together with Notice for the AGM, Directors report, Auditors reports thereon.

3. Decided to convene the 33rd Annual General meeting of the Company on 25th September 2020, through video conference or other audio visual means.

4.Decided to close the Register of members and Share transfer books of the Company from 21/09/2020 to 25/09/2020 (both days inclusive) for the purpose of the AGM.

5.Raise capital through preferential issue of warrants, which is subject to the approval of members at the ensuing Annual General Meeting of the Company.

6. Decided to obtain the approval of members as per Section 180(1)(a) of Companies Act,2013.

The meeting commenced at 4 p.m and concluded at 6.30 p.m on 29/07/2020.

Thanking You.
For Bal Pharma Limited

Shailesh Siroya
Managing Director



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph. : 41570813 / 19 Fax : 41570820



Independent Auditor's Report on Audited standalone Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Independent Auditor's Report

To the Board of Directors of Bal Pharma Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying standalone financial results of Bal Pharma Limited (herein after referred to as "the company") for the quarter and the year ended March 31, 2020, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these standalone financial results:

- i. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income and other financial information for the year ended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the Standalone annual financial results.



Emphasis of Matter

We draw attention to Note 6 to the financial results which explains COVID-19 and that it has caused significant disruptions in the business operations of companies across India and has caused significant accounting and auditing challenges. One such challenge being inability for the Company to conduct a physical verification of inventories for the year-end 31st March, 2020 due to Government having imposed restrictions during the lockdown on account of health, travel and safety concerns.

Inventories, being material to the financial statements/results of the Company, the Standard on Auditing (SA) 501, Audit Evidence - Specific Considerations for Selected items, cast a duty on us to obtain sufficient appropriate audit evidence regarding the existence and condition of inventories. Accordingly, we have performed alternative audit procedures in this regard to obtain sufficient appropriate audit evidence regarding the existence and condition of inventories.

We further refer to Note 3 with regard to recoverability of outstanding receivables from the subsidiary companies.

Our opinion is not modified with regard to above matters.

Management's Responsibilities for the Standalone Financial Results

These financial results, which is the responsibility of the Company's Management and approved by Board of Directors, has been compiled from the related audited interim financial statements. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related



Other Matter

The standalone financial results include the results for the quarter ended 31 March 2020, being the balancing figure between audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of the current financial year which were subjected to limited review by us.

for NSVM & Associates

Chartered Accountants

Firm Registration Number: 010072S



G.C.S Mani

Partner

Membership Number: 036508



Place: Bengaluru

Date: 29th July, 2020

UDIN: 20036508AAAACY8425



BAL PHARMA LIMITED
CIN: L85110KA1987PLC008363
Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluk, Bangalore 560 099
Phone : 080 41379500, Fax: 22354057, email: investor@balpharma.com
AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31.03.2020

(Rs in Lakhs)

Sl No.	Particulars	Standalone				
		Quarter Ended		Year ended		
		31 March 2020 Audited	31 December 2019 Unaudited	31 March 2019 Audited	31 March 2020 Audited	31 March 2019 Audited
I	Income					
	Revenue from operations	3,376.93	4,299.71	5,621.10	17,067.28	22,307.94
II	Other income	162.38	98.02	82.31	361.54	274.57
III	Total Income - (I)+(II)	3,539.31	4,397.73	5,703.41	17,428.82	22,582.51
IV	Expenses					
	a) Cost of materials consumed	1,652.64	1,947.88	3,027.52	7,943.71	11,363.87
	b) Purchase of Stock-in-trade	187.12	236.13	232.59	870.39	769.88
	c) Changes in inventories of finished goods, Stock-in-trade and work-in-progress	-238.78	-6.56	-594.48	-342.94	-440.65
	d) Employees benefits expenses	1,054.61	1,195.20	1,182.32	4,876.91	4,845.35
	f) Finance costs	300.48	280.34	364.34	1,241.57	1,252.86
	g) Depreciation and amortization expense	303.12	134.97	236.65	702.65	611.50
	h) Other expenses	641.39	753.91	1,107.02	3,093.40	3,738.65
	Total Expense - (IV)	3,901.07	4,541.87	5,556.46	18,385.69	22,141.45
V	Profit before Exceptional item and Tax (III-IV)	-361.26	-144.14	146.95	-956.87	-441.06
VI	Exceptional items	-	-	-	-	-
VII	Profit/ (Loss) before Tax (V-VI)	-361.26	-144.14	146.95	-956.87	-441.06
VIII	Tax Expense	53.05	56.76	-210.16	-4.17	-234.94
IX	Net Profit for the period	-414.31	-200.90	357.12	-952.70	676.00
X	Other Comprehensive Income (OCI)					
	- Items that may not be reclassified to Profit or loss	-41.11	-	-29.63	-41.11	-50.86
	- Income tax relating to items that will not be reclassified to profit or loss	10.69	-	8.24	10.69	8.24
	Total Other Comprehensive income, net of Income Tax	-30.42	-	-21.39	-30.42	-42.62
XI	Total Comprehensive income for the period (IX+X)	-444.73	-200.90	335.74	-983.12	633.38
XII	Paid up Equity Share Capital (Face value ₹ 10 per share)	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24
XIII	Other Equity	-	-	-	5,114.74	6,268.69
XIV	Earnings per share (Face value of ₹ 10 each)					
	Basic - in ₹	-2.92	-1.42	2.52	-6.72	4.77
	Diluted - in ₹	-2.92	-1.42	2.52	-6.72	4.77
	See accompanying notes to the audited standalone financial results					

Notes:

- The above audited standalone financial results of the Company as reviewed and recommended by the Audit Committee were approved by the Board of Directors at its meeting held on 29 July, 2020.
- The standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies to the extent applicable.
- The Company has an outstanding recoverability of ₹ 743.34 lakhs and ₹ 148.85 lakhs from its subsidiaries Lifezen Healthcare Private Limited and Balace Clinic LLP respectively. The said subsidiaries have incurred losses and have a negative networth. However the Management is confident that with infusion of additional funds, introduction of new brands and with renewed marketing efforts, the companies can revive and the amounts can be recovered.
- Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", and applied to all lease contracts existing on April 01, 2019 using the modified retrospective method. Accordingly, the comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. The Company has recognised a lease liability measured at the present value of the remaining lease payments, and right-of-use (ROU) asset at an amount equal to lease liability. The impact on the profit and earnings per share is ₹ 42.45 lakhs and ₹ 0.3 per share. The Right-of-use assets for year ended 31 March 2020 has been presented under property, plant and equipment.
- The Company has not received any intimation or information with regards to its vendors registration as a Micro, Small and medium enterprises. Accordingly, the entire dues to vendors have been classified as payable to other than MSMEs.
- The Company has considered the possible effects which may result from pandemic relating to COVID. The Company's manufacturing operations remained partially affected during the initial phase of lockdown. Subsequently, with a view to ensuring minimal disruption, the Company took certain measures to ensure business continuity. The Company continues to monitor the impact of Covid-19 on its business and various aspects. Due care has been exercised, in concluding on significant accounting judgements and estimates, including in relation to recoverability of receivables, assessment of impairment of intangibles, investments and inventory, while preparing the Company's Financial Results as of and for the year ended March 31, 2020. The management expects no impairment to the carrying amounts of these assets based on the information available to date. The Management will continue to closely monitor any changes to future economic conditions and assess its impact on the operations.
- The Company has only one reportable segment which is 'Pharmaceuticals'.
- The figures for the quarter ended March 31, 2020 and March 31, 2019 are the balancing figures between the Audited figures in respect of the full Financial Year and the Unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to Limited Review by the Statutory Auditor of the Company.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the period presentation.

Place: Bengaluru
Date: 29th July 2020



For Bal Pharma Limited

Shailesh D Siroya
Shailesh D Siroya
Managing Director

BAL PHARMA LIMITED

CIN: L85110KA1987PLC008368

21-22, Bommasandra, Industrial Area, Bengaluru - 562158, Karnataka

Balance Sheet as at 31st March, 2020

Particulars	As at 31 March 2020	As at 31 March 2019
ASSETS		
Non-current assets		
Property, Plant and Equipment	4,974.43	5,127.00
Capital work-in-progress	10.58	5.68
Intangible Assets	639.09	567.09
Financial assets		
- Investments	741.69	744.19
- Loans	24.50	73.12
- Other financial assets	156.10	253.86
Deferred tax assets (Net)		
Other non-current assets	137.69	94.83
	<u>6,684.08</u>	<u>6,865.77</u>
Current assets		
Inventories	6,705.62	6,951.58
Financial assets		
- Trade receivable	5,166.35	6,569.33
- Loans	1,743.71	1,358.16
- Cash and cash equivalents	67.64	219.74
- Other bank balances	227.31	188.75
- Other financial assets	182.00	113.70
Current tax assets (Net)	9.78	-
Other current assets	3,096.01	3,449.20
	<u>17,198.41</u>	<u>18,850.46</u>
	<u>23,882.49</u>	<u>25,716.23</u>
EQUITY & LIABILITIES		
Equity		
Equity share capital	1,417.24	1,417.24
Other equity	5,114.74	6,268.71
	<u>6,531.98</u>	<u>7,685.95</u>
LIABILITIES		
Non-current liabilities		
Financial liabilities		
- Borrowings	2,314.66	2,875.59
- Other financial liabilities	267.42	164.59
Provisions	354.64	266.08
Deferred tax liabilities (Net)	418.06	418.06
Other non-current liabilities	-	-
	<u>3,354.79</u>	<u>3,724.33</u>
Current liabilities		
Financial liabilities		
- Borrowings	7,060.63	6,805.83
- Trade payables		
Due to Micro, Small and Medium Enterprises	-	-
Due to Other than Micro, small and Medium Enterprises	3,945.15	4,749.08
- Other financial liabilities	1,431.30	1,353.07
Other current liabilities	1,508.93	1,302.23
Provisions	49.29	49.86
Current tax liabilities (Net)	-0.00	45.89
	<u>13,995.30</u>	<u>14,305.96</u>
	<u>23,882.07</u>	<u>25,716.24</u>



BAL PHARMA LIMITED
CIN: L85110KA1987PLC008368
21-22, Bommasandra, Industrial Area, Bengaluru - 562158, Karnataka
Cash Flow Statements for the Year ended 31st March, 2020

Particulars	For the year ended 31 March 2020	For the year ended 31 March 2019
₹ in Lakhs		
Cash flow from operating activities:		
(Loss) before tax	(907.62)	441.06
Adjustments:		
- Interest income	(209.63)	(222.45)
- (Gain)/Loss on sale of Fixed Asset	(5.25)	(0.44)
- Balances written off as no more payable	(45.47)	(2.91)
- Unrealised Foreign (Gain)/Loss	(10.39)	(87.48)
- Finance cost (including effect of amortisation of processing fees)	1,241.57	1,252.85
- Interest on Income Tax	4.79	-
- Rental Expense(IND AS 116)	(80.53)	-
- Balances written off as no more receivable	31.95	-
- Depreciation and amortisation	702.65	611.50
- Expected Credit Losses	22.38	16.40
- Impairment on Investments	2.50	-
Operating cash flow before working capital changes	746.94	2,008.54
Changes in		
- Decrease/(Increase) in Inventories	196.71	(334.90)
- Decrease/(Increase) in Trade receivables	1,239.35	(92.58)
- Decrease/(Increase) in Loans	36.87	51.68
- Decrease/(Increase) in Financial Assets (Current and Non current)	(14.12)	(0.86)
- Decrease/(Increase) in Other Assets (Current and Non current)	310.33	501.08
- Increase/(Decrease) in Trade payables	(812.75)	(245.53)
- Increase/(Decrease) in Other Financial liabilities (Current and Non current)	383.11	(510.76)
- Increase/(Decrease) in Other Bank Balances	-	-
- Increase/(Decrease) in Provisions	87.99	15.61
Cash (used in)/ generated from operations	2,174.43	1,392.28
Income taxes (paid)/ refund	(17.21)	(237.58)
Net cash generated (used in) operating activities	2,157.22	1,154.69
Cash flow from investing activities:		
Purchase of Property, Plant & Equipment including intangible assets and capital work-in-progress	(359.92)	(477.80)
Intercompany Deposit to Subsidiary	-	(437.63)
Interest Income from subsidiary	-	-
Investment in Subsidiaries	-	(92.60)
Proceeds from sale of fixed assets	0.53	1.84
Employees	-	-
Decrease/(increase) in fixed deposits	9.76	(244.75)
Interest received	33.96	53.22
Net cash (used in) investing activities	-315.68	-1,197.72
Cash flow from financing activities:		
Proceeds from / (repayment) of long term borrowings	(879.67)	(493.77)
Proceeds from / (repayment) of short term borrowings	254.79	1,877.12
Dividend Paid including dividend distribution tax	(141.72)	(147.21)
Interest Paid (Gross)	(1,227.04)	(1,231.33)
Net cash generated from financing activities	-1,993.65	4.81
Net (decrease)/ increase in cash and cash equivalents	(152.10)	(38.22)
Cash and cash equivalents at the beginning of the year	219.74	257.96
Cash and cash equivalents at the end of the year	67.64	219.74
Cash and cash equivalents comprise of:		
Cash on hand	17.04	4.86
Balances with banks	-	-
- in current accounts	24.37	176.11
- in unpaid dividend accounts	26.22	38.77
	67.64	219.74

Shree

